PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Download this slideset on the current advances and evolving landscape of PARP inhibitors for patients with pancreatic cancer.
Dirk Arnold, MD, PhD
person default
Michel Ducreux, MD, PhD
Philip Agop Philip, MD, PhD, FRCP
Format: Microsoft PowerPoint (.ppt)
File Size: 882 KB
Released: December 14, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Related Content

From Clinical Care Options (CCO), downloadable PDF featuring key points from expert discussion on PARP inhibitors in treatment of pancreatic cancer

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Video from Clinical Care Options (CCO): Expert insights on biomarker-driven treatment for gastrointestinal (GI) cancers

Pashtoon M. Kasi, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Expert commentary on biomarkers to guide therapy for patients with gastrointestinal cancers, from Clinical Care Options (CCO)

Christopher H. Lieu, MD Released: April 27, 2022

Clinical Care Options (CCO): Experts review key data for gastric, rectal, liver, hepatobiliary tract, and pancreas cancers from the 2022 ASCO Gastrointestinal Cancers Symposium and the ASCO Plenary Series

Manish A. Shah, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 20, 2022 Expired: April 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings